Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025)
Historic EBITDA Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 107.87%.
- Keros Therapeutics' EBITDA Margin rose 150099200.0% to 107.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.67%, marking a year-over-year increase of 313592900.0%. This contributed to the annual value of 5938.96% for FY2024, which is 1066047500.0% up from last year.
- Latest data reveals that Keros Therapeutics reported EBITDA Margin of 107.87% as of Q3 2025, which was up 150099200.0% from 219.16% recorded in Q2 2025.
- Keros Therapeutics' 5-year EBITDA Margin high stood at 1576900.0% for Q1 2021, and its period low was 541000.0% during Q3 2023.
- In the last 5 years, Keros Therapeutics' EBITDA Margin had a median value of 1750.62% in 2024 and averaged 59681.03%.
- As far as peak fluctuations go, Keros Therapeutics' EBITDA Margin crashed by 2000000000bps in 2022, and later soared by 2000000000bps in 2024.
- Keros Therapeutics' EBITDA Margin (Quarter) stood at 27.18% in 2021, then tumbled by -393bps to 134.03% in 2022, then crashed by -24137bps to 32486.01% in 2023, then surged by 95bps to 1750.62% in 2024, then surged by 94bps to 107.87% in 2025.
- Its last three reported values are 107.87% in Q3 2025, 219.16% for Q2 2025, and 71.97% during Q1 2025.